Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces it has acquired MedPharmics, a multi-site company based in the US. The acquisition brings Velocity’s total number of locations to 40 sites across 19 U.S. states and Europe. With this acquisition, Velocity will add just over 100 employees of diversified backgrounds to the … Read more
Meridian Clinical Research, now part of Velocity Clinical Research, enrolled the first participant in Moderna’s Phase 1 clinical trial for an Epstein-Barr virus (EBV) vaccine candidate (mRNA-1189). Congratulations to Moderna, and to Brandon Essink, MD, CPI, and the team in Omaha, Nebraska! Read the Moderna press release >
Meridian Clinical Research, now part of Velocity Clinical Research, won the first ever Excellence in Patient Centricity Award from the Society for Clinical Research Sites (SCRS). The award was presented to Meridian at the 2021 Global Site Solutions Summit in Hollywood, FL. Sponsored by Sanofi, the award was created to, “Celebrate a clinical research site … Read more
Officials from the U.S. Department of Health and Human Services (HHS) visited with leaders from Meridian Clinical Research (now part of Velocity Clinical Research) in Savannah, GA. Following a tour of the company’s internal medicine site in Savannah, the group held a roundtable to discuss patient recruitment efforts and the research conducted for COVID-19 vaccine clinical … Read more
Meridian Clinical Research, now part of Velocity Clinical Research, won the 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site. The company was also part of Platinum Research Network, which won the ViE award for Best Clinical Trial Network. “It’s incredible to earn these awards when vaccine trials are the industry’s priority and … Read more
Brandon Essink, MD, CPI, is a co-principal investigator for the Phase 3 clinical trial of Moderna’s COVID-19 vaccine. Read the full National Institutes of Health (NIH) press release: https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins
The first participant in the Moderna Phase 3 COVID-19 vaccine trial was enrolled this morning by Dr. Paul Bradley, Principal Investigator at Meridian’s (now Velcoity Clinical Research) internal medicine site in Savannah, GA. Compliments to Moderna on this significant milestone for its mRNA vaccine candidate (mRNA-1273) against COVID-19. 📰 Full release: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-phase-3-cove-study-mrna-vaccine-against-covid
The first participant in the Moderna Phase 2 COVID-19 vaccine trial was enrolled this morning by Keith Vrbicky, MD, Meridian (now Velocity Clinical Research) Principal Investigator in Norfolk, NE. Congratulations to Moderna for making remarkable progress on its mRNA vaccine against novel coronavirus. 📰 Full release: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-each-age-cohort-dosed-phase
Bounphone Chanthavong (Willow), MPH, CCRC, is the 2019 PharmaTimes Clinical Research Coordinator of the Year! Willow is a research coordinator at Meridian’s (now Velocity Clinical Research) neurology site in Savannah, GA, and won the award on May 4, 2019, after a three-stage competition involving an initial online test, a written essay challenge, and an in-person presentation in … Read more
Results from clinical trials performed at Meridian Clinical Research (now Velocity Clinical Research) sites in Norfolk, NE, Omaha, NE, and Savannah, GA, were recently published in two prestigious medical journals. Brandon Essink, MD, CPI, co-authored an article published in Vaccine. Dr. Essink led a study at the company’s Omaha site as part of a successful clinical … Read more